US support for waiving COVID-19 vaccine patent rights puts pressure on drugmakers – but what would a waiver actually look like?

US support for waiving COVID-19 vaccine patent rights puts pressure on drugmakers – but what would a waiver actually look like? The waiver could build on the existing system for compulsory licensing of patents and extend that to trade secrets and knowledge. The negotiations around access to HIV/AIDS medicines in the 1990s ended up with a similar framework.

No comments:

Post a Comment